Finally, we demonstrated that siRNA-mediated SCFD2 silencing suppressed in vivo tumor growth of tamoxifen-resistant breast cancer cells, suggesting that SCFD2 can be a promising therapeutic target of tamoxifen-resistant breast cancer. This evidence concerns the gene SCFD2 and breast cancer.